P1.04-29 Second or Third Line Nivolumab Versus First Line Nivolumab in Patients With Previously Treated Advanced Non Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.744
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Third-Line Nivolumab Monotherapy in Recurrent Small Cell Lung Cancer: CheckMate 032

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

179P: Nivolumab Monotherapy in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice in a Spanish Center

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2016English

Pharmacoeconomic Study of Pembrolizumab and Nivolumab in the Second Line of Therapy of Advanced Non-Small Cell Lung Cancer

Effective Pharmacotherapy
2019English

P1.04-35 Quick Progression (QP) in Patients Treated by Nivolumab (IO) in 2nd Line or More for Non-Small Cell Lung Cancer: ERORECI Study (GFPC 2016-04)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Treatment Paradigms for Patients With Metastatic Non-Small-Cell Lung Cancer: First-, Second-, and Third-Line

Current Oncology
Oncology
2012English

Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab

JAMA Oncology
Cancer ResearchOncology
2019English

Cost-Effectiveness of First-Line Therapy for Advanced Non-Small Cell Lung Cancer (Nsclc)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Predictive Role of Plasmatic Biomarkers in Advanced Non-Small Cell Lung Cancer Treated by Nivolumab

OncoImmunology
OncologyAllergyImmunology
2018English

Nivolumab in Metastatic Non–Small Cell Lung Cancer

Journal of the Advanced Practitioner in Oncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy